# AlgoTherapeutix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/algotherapeutix

- Industry: Biotechnology
- Headquarters: Suresnes, France
- Website: www.algotx.com
- Total disclosed funding: $29M
- Latest round: Series B (Mar 14, 2023)
- Investors on record: 5

## About

Based in France, AlgoTherapeutix SAS is a biotechnology company focused on creating innovative, non-opioid therapies for complex pain conditions, with a special emphasis on neuropathic pain associated with chemotherapy.AlgoTherapeutix SAS, founded in 2018 and headquartered in Suresnes, France, specializes in developing non-opioid treatments for pain. The company has completed five deals, with its most recent funding round being a Series B, which raised EUR 20.000 mn on March 14, 2023, led by Turenne Groupe, alongside investors Bpifrance Investissement, Omnes Capital, and UI Investissement. The founder's prior entrepreneurial experience is not publicly documented.AlgoTherapeutix SAS specializes in developing innovative, non-opioid therapies for complex pain conditions, particularly targeting Chemotherapy-Induced Peripheral Neuropathy (CIPN). Their flagship product, ATX01, is currently in Phase 2 clinical development and is designed to alleviate CIPN pain by inhibiting specific nociceptive sodium channels. The company focuses on delivering its specialized therapies primarily within the healthcare sector across the United States and Europe.AlgoTherapeutix SAS generates revenue through partnerships with healthcare professionals and institutions, providing treatments for pain conditions. Their business operations are centered on B2B transactions that facilitate the delivery of ATX01 and future products directly to clinics and hospitals, utilizing sales agreements with volume-based pricing strategies that cater to specific patient populations.Moving forward, AlgoTherapeutix SAS plans to utilize the recent EUR 1 million grant funding received in March 2023 to demonstrate the clinical effectiveness of ATX01 in treating neuropathic pain. The company aims to expand its market presence in the United States and Europe by continuing to develop and launch new products tailored for patients with difficult-to-treat pain conditions.

## Funding rounds

- Series B, Mar 14, 2023, $21M — Omnes Capital, Turenne Groupe, UI Investissement, Bpifrance Investissement
- Series A, Jan 11, 2021, $7.4M — Omnes Capital, Bpifrance

## Investors

- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series A, Series B
- Bpifrance — Series A
- Turenne Groupe (https://capitalatlas.ai/funds/turenne-groupe) — Series B
- UI Investissement (https://capitalatlas.ai/funds/ui-investissement) — Series B
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series B